ES2172474A1 - Derivados de glutarimida como agentes terapeuticos. - Google Patents

Derivados de glutarimida como agentes terapeuticos.

Info

Publication number
ES2172474A1
ES2172474A1 ES200100488A ES200100488A ES2172474A1 ES 2172474 A1 ES2172474 A1 ES 2172474A1 ES 200100488 A ES200100488 A ES 200100488A ES 200100488 A ES200100488 A ES 200100488A ES 2172474 A1 ES2172474 A1 ES 2172474A1
Authority
ES
Spain
Prior art keywords
derivatives
imide
alpha
salts
therapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100488A
Other languages
English (en)
Other versions
ES2172474B1 (es
Inventor
Brana Miguel Fernandez
Diaz Loereto Anorbe
Martin Gema Dominguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Universitaria San Pablo CEU
Original Assignee
Fundacion Universitaria San Pablo CEU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Universitaria San Pablo CEU filed Critical Fundacion Universitaria San Pablo CEU
Priority to ES200100488A priority Critical patent/ES2172474B1/es
Priority to PCT/ES2002/000092 priority patent/WO2002070480A1/es
Publication of ES2172474A1 publication Critical patent/ES2172474A1/es
Application granted granted Critical
Publication of ES2172474B1 publication Critical patent/ES2172474B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Nuevos derivados de glutarimida de fórmula general I, así como sus homólogos de naturaleza dimérica I-Q-I, donde Z puede ser una imida o una bisimida de diversos tipos, e Y y Q pueden ser diferentes tipos de átomos, cadenas o grupos de química orgánica, caracterizados dichos derivados por su actividad antiangiogénica concominante de los tumores sólidos y por su acción inhibidora del factor de necrosis tumoral alfa (TNF-). Estos compuestos son preparados mediante los métodos generales de síntesis de imidas, obteniéndose las diferentes sales, profármacos de sales y medicamentos para su utilización en la terapia coadyuvante anticancerosa, por cualquier medio disponible en clínica.
ES200100488A 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos. Expired - Fee Related ES2172474B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200100488A ES2172474B1 (es) 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos.
PCT/ES2002/000092 WO2002070480A1 (es) 2001-03-01 2002-03-01 Derivados de glutarimida como agentes terapeuticos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100488A ES2172474B1 (es) 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos.

Publications (2)

Publication Number Publication Date
ES2172474A1 true ES2172474A1 (es) 2002-09-16
ES2172474B1 ES2172474B1 (es) 2004-01-16

Family

ID=8496938

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100488A Expired - Fee Related ES2172474B1 (es) 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos.

Country Status (2)

Country Link
ES (1) ES2172474B1 (es)
WO (1) WO2002070480A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
TWI601722B (zh) 2011-03-11 2017-10-11 西建公司 ３-（５-胺基-２-甲基-４-氧基-４ｈ-喹唑啉-３-基）-六氫吡啶-２，６-二酮之固體型式及其醫藥組合物及用途
CN108101887A (zh) * 2016-11-24 2018-06-01 天津和美生物技术有限公司 哌啶-2,6-二酮衍生物及其在治疗克罗恩氏病中的用途
EP3609482A4 (en) * 2017-04-11 2021-01-13 John K. Thottathil NEW ALPHA-HYDROXY CARBOXYLIC ACID AND DERIVATIVES AND OTHER MEDICINAL PRODUCTS FAT-TYPE AMID AND IMIDE OF AMPHETAMINE COMPOUNDS AND THEIR USES
JP2022507267A (ja) 2018-11-13 2022-01-18 バイオセリックス， インコーポレイテッド 置換イソインドリノン

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1075420A (en) * 1965-05-08 1967-07-12 Gruenenthal Chemie Cyclic imide compounds and a process for their production
US3553217A (en) * 1968-10-18 1971-01-05 Aldrich Chem Co Inc 2-(quinolinimido)glutarimide
WO1998044908A1 (en) * 1997-04-07 1998-10-15 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating epithelial growth
EP1004580A2 (en) * 1993-07-02 2000-05-31 Celgene Corporation Imides as inhibitors of TNF alpha

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1075420A (en) * 1965-05-08 1967-07-12 Gruenenthal Chemie Cyclic imide compounds and a process for their production
US3553217A (en) * 1968-10-18 1971-01-05 Aldrich Chem Co Inc 2-(quinolinimido)glutarimide
EP1004580A2 (en) * 1993-07-02 2000-05-31 Celgene Corporation Imides as inhibitors of TNF alpha
WO1998044908A1 (en) * 1997-04-07 1998-10-15 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating epithelial growth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOVACS, K. y col. Synthesis of glutamine and pyroglutamyl glutamine derivatives substituted in carboxamide nitrogen. Acta Phys. Chemical, 1996, Vol. 12, No 3-4, paginas 143-150 (compuesto con RN 15263-23-7; resumen). HCAPLUS [en linea] [recuperado el 03.06.2002]. Recuperado de STN International, Columbus, Ohio (EE.UU.). No de acceso 1967:454423. *

Also Published As

Publication number Publication date
WO2002070480A1 (es) 2002-09-12
ES2172474B1 (es) 2004-01-16

Similar Documents

Publication Publication Date Title
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
GEP20084435B (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
GEP20074213B (en) Novel inhibitors of kinases
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
MXPA06000276A (es) Indolinona hidrazidas como inhibidores de c-met.
DE60318177D1 (de) Rho-kinase inhibitoren
TW200519106A (en) Organic compounds
TW200614990A (en) Methods for preparing indazole compounds
HK1074794A1 (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
NO20070378L (no) Bis(tio-hydrazidamid)-salter for behandling av kreft
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
SG162722A1 (en) N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
ATE343575T1 (de) Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
SE0401970D0 (sv) Novel compounds
EA200702672A1 (ru) Производные индола, обладающие противоопухолевой активностью
ES2172474A1 (es) Derivados de glutarimida como agentes terapeuticos.
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020916

Kind code of ref document: A1

Effective date: 20020916

FG2A Definitive protection

Ref document number: 2172474B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210625